The Entero Healthcare Solutions IPO came to the market in February 2024. The company operates in the healthcare supply chain industry, which connects pharmaceutical manufacturers with pharmacies, hospitals, and clinics across India.
But investors want to know one thing: Was the Entero Healthcare IPO good or bad for investors?
Let’s look at the company, IPO details, listing performance, strengths, risks, and the final verdict.
About Entero Healthcare Solutions
Entero Healthcare Solutions Limited is a technology-driven healthcare distribution company. It supplies pharmaceutical and healthcare products to pharmacies, hospitals, and clinics through a large distribution network.
Key facts about the business:
- Founded in 2018
- Works with 1,900+ healthcare product manufacturers
- Supplies more than 64,500 products
- Serves 81,000+ pharmacies and 3,400 hospitals across India
The company’s business model focuses on building a nationwide healthcare supply chain platform.
Entero Healthcare IPO Details
Here are the main details of the IPO:
- IPO opening date: 9 February 2024
- IPO closing date: 13 February 2024
- Listing date: 16 February 2024
- Price band: ₹1,195 – ₹1,258 per share
- Lot size: 11 shares
- Issue size: about ₹1,600 crore
- Listing exchanges: NSE and BSE
The IPO consisted of:
- Fresh issue: ₹1,000 crore
- Offer for sale: ₹600 crore
The company planned to use fresh funds mainly for working capital, acquisitions, and expansion.
Subscription Demand
Investor demand for the IPO was moderate.
- Overall subscription: about 53 times
Category-wise demand:
- QIB (institutional investors): 2.28x
- Retail investors: 1.33x
- NII investors: 0.22x
This indicates that the IPO received average investor interest, not extremely strong demand.
Listing Performance
The IPO did not deliver listing gains.
- Issue price: ₹1,258
- Listing price: around ₹1,149 – ₹1,228
- Listing loss: about 2–8%
This means investors who sold shares on listing day faced a small loss.
Current Stock Performance
As of 2026, the stock trades around ₹1,090 – ₹1,150 with a market cap near ₹5,000 crore.
Important financial indicators:
- P/E ratio around 38
- ROE around 6%
This shows the company is growing but still has moderate profitability.
Strengths of Entero Healthcare
1. Growing Healthcare Distribution Market
India’s pharmaceutical market is expanding rapidly, creating demand for efficient supply chain companies.
2. Large Distribution Network
The company operates 73 warehouses across 37 cities, serving thousands of pharmacies and hospitals.
3. Rapid Revenue Growth
Within just a few years of operation, the company scaled revenue to over ₹2,500 crore.
4. Technology-Driven Platform
Entero uses technology platforms and data analytics to manage healthcare distribution efficiently.
Risks and Weaknesses
1. Weak Listing Performance
The IPO listed below its issue price, disappointing short-term investors.
2. Low Profitability
Return ratios like ROE around 6% are relatively low for a growing company.
3. High Working Capital Requirement
Healthcare distribution requires large inventories and logistics costs.
4. Past Losses
The company reported losses in previous financial years before turning profitable.
Financial Snapshot
Key numbers include:
- Revenue above ₹5,600 crore
- Profit around ₹128 crore
- Market cap about ₹5,000 crore
These figures show the company has large revenue but moderate margins.
Final Verdict – Is Entero Healthcare IPO Good or Bad?
Short answer: The Entero Healthcare IPO was average, not very good for listing gains.
Positive Points
- Large healthcare distribution network
- Rapid revenue growth
- Expanding pharmaceutical market
Negative Points
- Listing loss
- Moderate investor demand
- Low profitability ratios
Overall Rating
6/10 – Average IPO.
Short-term investors did not receive strong listing gains. Long-term investors may benefit if the company successfully expands its healthcare distribution network across India.
